Effect of beza®brate on plasma homocysteine concentration in men with lower extremity arterial disease In the Lower Extremity Arterial Disease Event Reduction (LEADER) trial [1] , a randomized trial of beza®brate compared with placebo in men with lower extremity arterial disease (LEAD), beza®brate non-signi®cantly reduced the combined end-points of coronary death, fatal and non-fatal myocardial infarction and stroke despite achieving the anticipated reductions in total and LDL-cholesterol, triglycerides and plasma ®brinogen and elevation of HDL-cholesterol [1] . This limited clinical bene®t might be because beza®brate had adverse effects on other variables, one candidate being homocysteine, a novel risk factor for cardiovascular disease. We have therefore measured plasma homocysteine in participants in LEADER. The participants have been described elsewhere [1] : 1568 patients with LEAD were recruited through 85 practices in the Medical Research Council's General Practice Research Framework and through nine hospital vascular clinics.
Blood samples were taken at baseline and after 3 and 6 months of treatment from one of the participating vascular clinics (Glasgow Royal In®rmary). Homocysteine samples were collected in three further vascular clinics only after the initiation of treatment. Samples were collected into dipotassium EDTA and placed on ice until centrifugation at 2000 Â g. The samples were posted to the central laboratory and stored at À70 8C until analysis. Homocysteine was measured by¯uor-escence polarization immunoassay (Abbott Laboratories, Maidenhead, UK).
Plasma homocysteine was log-transformed and means are geometric with 1 SD speci®ed as a multiple of the mean. Levels were adjusted for serum creatinine using the regression estimate , so all on-treatment values were combined. Differences between groups were tested by two-sample t-tests using the change in the log-transformed values. Table 1 shows that in those with both baseline and on-treatment measures there was a signi®cant mean increase of 35.6% in plasma homocysteine with beza®brate but not with placebo (P < 0.0001) and homocysteine was signi®cantly higher in those receiving beza®brate than in those receiving placebo (P 0.0002). After adjustment for serum creatinine, the increase in homocysteine with beza®brate remained highly signi®cant, the mean value being 25.9% higher than baseline, whereas it was virtually unchanged with placebo (P < 0.0001). A very similar effect was observed when these on-treatment results were combined with those from the three clinics where only on-treatment samples were collected, assuming baseline samples were similar (the unequal numbers in the two groups were nevertheless based on random allocation).
The 4.5 mmol L À1 (35.6%) rise in homocysteine in men with LEAD taking beza®brate may have prevented the favorable lipid and ®brinogen responses leading to a reduction in clinical outcomes. A recent meta-analysis of prospective studies [2] suggests that a 5 mmol L À1 increase in homocysteine increases the risk of ischemic heart disease by 34% (95% con®dence interval 1.22, 1.47) and stroke by 59% (1.30, 1.95). Especially if this increase were manifest soon after the increase in homocysteine, the increase of 4.5 mmol L À1 with beza®brate might be suf®cient to counter any bene®ts of lipid and ®brinogen alterations. In LEADER there was a non-signi®cant reduction in major coronary events (relative risk 0.81, 0.60, 1.08) but a nonsigni®cant increase in stroke (relative risk 1.34, 0.80, 2.01), which is consistent with an adverse effect of beza®brate mediated through homocysteine. Support for the clinical signi®cance of short-term changes in plasma homocysteine comes from the ®nding that homocysteine lowering by vitamin supplementation reduced the risk of coronary re-stenosis within 6 months after angioplasty [3] .
Effects of ®brates on homocysteine have previously been reported [4±6] . Changes in the levels of the vitamins involved in homocysteine metabolism (folic acid, vitamin B 12 and vitamin B 6 ) are unlikely to be the mechanism for the ®ndings [5] .There is uncertainty as to whether or not the rise in serum creatinine with ®brates is due to a reduction in creatinine clearance or to increased synthesis of creatinine with normal creatinine clearance and therefore whether or not alteration in renal function is the explanation for the rise in homocysteine [5, 6] . Adjustment of homocysteine for serum creatinine in our study did not materially alter the effect of beza®brate on homocysteine, suggesting that alteration in renal function is an unlikely explanation for the effect of beza®brate on homocysteine that we observed.
Two studies have shown that coadministration of feno®brate and folic acid with or without vitamin B 6 and B 12 signi®cantly reduced the ®brate-induced rise in homocysteine [7, 8] . Further evaluation of the effect of folic acid given concurrently with beza®brate is now required to see if, by lowering homocysteine, this allows the potentially bene®cial effects of beza®brate on coronary heart disease and stroke to be fully expressed. Alternatively, ®brates that do not cause elevation of plasma homocysteine could be developed. 
